Elevated free fatty acids and impaired adiponectin bioactivity contribute to reduced SOD2 protein in monocytes of type 2 diabetes patients.
Bauer
Sabrina
S
Department of Internal Medicine I, Regensburg University Hospital, D-93042 Regensburg, Germany.
Wanninger
Josef
J
Neumeier
Markus
M
Wurm
Sylvia
S
Weigert
Johanna
J
Kopp
Andrea
A
Bala
Margarita
M
Schäffler
Andreas
A
Aslanidis
Charalampos
C
Buechler
Christa
C
D017667:Adipocytes / Q000378:metabolism; D052242:Adiponectin / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D015992:Body Mass Index; D016022:Case-Control Studies; D002478:Cells, Cultured; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000378:metabolism* / Q000494:pharmacology; D000099156:Superoxide Dismutase 2
D052242:Adiponectin; D005230:Fatty Acids, Nonesterified; D011994:Recombinant Proteins; D013482:Superoxide Dismutase; D000099156:Superoxide Dismutase 2